Phase 1 N=23 Three Way Crossover Closed Loop Study With Xeris Glucagon
Type1diabetes
Primary: Percent of Time With Sensed Glucose < 70 mg/dl — 0; 8.3; 4.2 percentage 4 hrs post exercise on Day 1
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=26 A Study of Various Formulations of LY900014 in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Area Under The Concentration Curve (AUC 0-30mins) of Insulin Lispro — 245; 295; 251; 253 picomol per hours per liter (pmol*h/L)
Phase 1 N=27 An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma
Multiple Myeloma (MM)
Primary: Safety Profile of Acalabrutinib With and Without Dexamethasone — 13; 14; 7; 7 Participants
Phase 1 N=25 Drug Interaction and Self Administration Studies of Compounds for Cocaine Use Disorder
Cocaine Use Disorder
Primary: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) - Heart Rate — 7.8; 4.96 beats per minute
Phase 1 N=12 A Trial to Evaluate the Effect of the Proton Pump Inhibitor Esomeprazole on the Single-dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants
Healthy Volunteers
Primary: Cmax: Maximum Observed Plasma Concentration for TAK-906 — 19.76; 17.24 nanogram per milliliter (ng/mL) — p=0.3011
Phase 1 N=22 Positron Emission Tomography (PET) Study Investigating Dopamine and Serotonin Receptor Occupancy After Multiple Oral Dosing of Lu AF35700
Schizophrenia
Primary: Emax D1 Dopamine — 81.9 percentage
Phase 1 N=30 A Study to Assess the PK and Safety of PT010 in Subjects With COPD Following Single and Repeat Dose
Chronic Obstructive Pulmonary Disease
Primary: Maximum Plasma Concentration (Cmax) - Budesonide — 709.3 pg/mL
Phase 1 N=40 A Study to Determine the Maximum Tolerated Dose of an Investigational Drug in Subjects With Schizophrenia
Schizophrenia
Primary: Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs ) Leading to Study Discontinuation — 4; 4; 2; 4 count of participants
Phase 1 N=80 University of Alabama at Birmingham (UAB) Adult CBD Program
Epilepsy · Seizures
Primary: Number of Participants With Severe Adverse Events (SAEs) (Increase in Seizure Frequency by More Than 100% Leading to Emergency Room Visit or Hospitalization). — 0…
Phase 1 N=14 A Study to Investigate the Effect of CYP3A Inhibition on the Pharmacokinetics of RO7017773 in Healthy Participants
Healthy Volunteers
Primary: Maximum Concentration (Cmax) of RO7017773 in Plasma — 458; 516 ng/mL
Phase 1 N=25 A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers
GastroEsophageal Cancer
Primary: The Completion Rate of Chemotherapy in Combination With Chemoradiation — 23 Participants
Phase 1 N=60 Safety of Lactobacillus Reuteri in Healthy Children Aged 2-24 Months
Healthy
Primary: Number of Participants With Positive Blood Culture for L. Reuteri — 0; 0 Participants
Phase 1 N=236 Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
Pancreatic Cancer · Non-small Cell Lung Cancer · Esophagogastric Cancer
Primary: Percentage of Participants Experiencing Treatment-Emergent Adverse Events — 100.0; 100.0; 83.3; 100.0 percentage of participants
Phase 1 N=24 A Study of LY900014 Administered in Participants With Type 1 Diabetes Using an Insulin Pump
Diabetes Mellitus, Type 1
Primary: Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve From Time Zero to 5 Hours(h) (AUC [0-5 h]) Following Administration of Each Study Arm With a…
Phase 1 N=49 A Study to Compare 2 Formulations of LY900014 in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Insulin Lispro Area Under Plasma Concentration Curve Zero to 10 Hours (AUC[0-10]) — 1760; 1550 hours times picomols per milliliter